Thermo Fisher Scientific SHOC2 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1-2 µg/mL

-

Immunohistochemistry (IHC)

5 µg/mL

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A 21 amino acid peptide near the amino terminus of human SHOC2. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:SHOC2,uniProtId:Q9UQ13-1,ncbiNodeId:9606,antigenRange:1,antigenLength:582,antigenImageFileName:PA5-20762_SHOC2_Q9UQ13-1_Rabbit.svg,antigenImageFileNamePDP:PA5-20762_SHOC2_Q9UQ13-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS

Contains

0.02% sodium azide

Storage conditions

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11151996

Product Specific Information

A suggested positive control is Jurkat cell lysate.

PA5-20762 can be used with blocking peptide PEP-0876.

Target Information

SHOC2 protein participates in protein binding / transferase activity in the fibroblast growth factor receptor signaling pathway and Ras protein signal transduction. It is a widely expressed protein composed almost entirely of leucine-rich repeats (LRR), with a lysine-rich sequence at the amino terminus and cytoplasmically localized. SHOC2 acts as a positive modulator of the RAS-MAPK signaling cascade, which is elicited by EGL-15 and LET-23 and mediated by LET-60. SHOC2 together with protein phosphatase 1c (PP1c) forms a highly specific M-Ras effector complex and is essential for activation of the MAPK pathway by growth factors. Furthermore, in tumor cells with Ras gene mutations, inhibition of SHOC2 expression inhibits MAPK, but not PI3K activity. The SHOC2-PP1c holoenzyme provides an attractive therapeutic target for inhibition of the MAPK pathway in cancer. Recent studies show that aberrantly acquired N-myristoylation of SHOC2 causes human disease Noonan-like syndrome with loose anagen hair.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.